Psychoactive Research chemicals are new synthetic substances that are structurally similar to the original drug, while being functional analogs. Research on the effects of, and treatment for, abuse of these drugs is limited due to the fact that they’re fairly new and have avoided mainstream notice. Research chemicals do not have a lot of human consumption data, and thus harm-reduction and special care should be taken if choosing to ingest them.
Psychedelics are drugs which cause profound changes in a one’s perceptions of reality, otherwise known as hallucinations. While under the influence of hallucinogens, users might see images, hear sounds or feel sensations. These chemicals offer some of the most intense psychological experiences and care should be taken when ingesting them.
Disclaimer: Psychedelic drugs offer some of the most power and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.
Practice Harm Reduction. Proceed with Caution.
Also known as:
yl-1-azetidinyl][(8[German][ACD/IUPAC Name] β)-6-methyl-9,10-di dehydroergolin-8-yl ]methanon
yl-1-azetidinyl][(8[ACD/IUPAC Name] β)-6-methyl-9,10-di dehydroergolin-8-yl ]methanone
yl-1-azétidinyl][(8[French][ACD/IUPAC Name] β)-6-méthyl-9,10-di déhydroergolin-8-yl ]méthanone
- Lysergic acid 2,4-d
- Methanone, [(8β)-9,
10-didehydro-6-meth[ACD/Index Name] ylergolin-8-yl][(2S ,4S)-2,4-dimethyl-1 -azetidinyl]-
- [(2S, 4S)-2,4-dimet
hylacetidin-1-yl][([ACD/IUPAC Name] 8b)-6-methyl-9,10-d idehydroergol-8-yl] methanone
A lysergamide very similar to LSD usually distinguishable only by its shorter duration, though some subjective reports have noted it may be slightly more introspective and slightly less confusing.
In the 2000s, a team led by David E. Nichols at Purdue University set to develop a rigid analog of LSD with the diethylamide group constrained into an azetidine ring in order to map the binding site at the 5-HT2A receptor. LSZ has little to no history of human usage prior to 2012 when it appeared on some research chemical markets in the UK.
LSZ later gained international popularity through a small cluster of mail-order novel psychedelic shops that appeared in 2012. There have also been several unconfirmed reports of LSZ being synthesized in illicit laboratories and distributed on blotter paper or in liquid solution under names such as “Diazedine” and “λ” (or “Lambda”). LSZ is not considered to be addictive or physiologically toxic.
Nevertheless, adverse psychological reactions such as severe anxiety, paranoia and psychosis are always possible, particularly among those predisposed to mental illness. It is highly advised to use harm reduction practices if using this substance.
It contains a core structure of lysergic acid with an amine functional group bound to RN of the chemical structure.
This core polycyclic structure is an indole derivative, and has tryptamine and phenethylamine groups embedded within it. The structure contains a bicyclic hexahydroindole fused to a bicyclic quinoline group (lysergic acid).
At carbon 8 of the quinoline, an amide group is bound.
Additionally, the substitutions of the terminal nitrogen atom of the amide group form a 2,4-dimethylazetidide group.
LSZ is additionally substituted at carbon 6 with a methyl group. There are three possible stereoisomers around the azetidine ring with the (S,S)-(+) isomer being the most active.
It is slightly more potent than LSD itself in drug discrimination tests using trained rats.
|Common Name||Lysergic acid 2,4-dimethylazetidide|
|Systematic name||Lysergic acid 2,4-dimethylazet|
|SMILES||C[[email protected]]1C[[email protected]@H](N1C(=O)[[email protected]]2CN([[email protected]@H]3Cc4c[nH]c5c4c(ccc5)C3=C2)C)C|
|Avg. Mass||335.4427 Da|
|Monoisotopic Mass||335.199768 Da|
|LSZ Duration Data|
Interactions and Synergies
There are no existing interaction or synergy data for this drug.
|Effects||Euphoria, empathy, insight, brightened colour, Closed/Open eye visuals, enhanced tactile sensation, mental/physical stimulation, decreased appetite, pupil dilation, restlessness, change in perception, ego softening, sweating/chills, muscle tension, confusion, insomnia.|
|Marguis Test Result|
LSZ likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from LSZ’s efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
- Bodily control enhancement
- Pupil dilation
- Spontaneous physical sensations
- Tactile enhancement
- Analysis enhancement
- Conceptual thinking
- Creativity enhancement
- Emotion enhancement
- Immersion enhancement
- Increased music appreciation
- Memory suppression
- Novelty enhancement
- Personal bias suppression
- Spirituality enhancement
- Thought acceleration
- Thought disorganization
- Thought loops
- Time distortion
- Unity and interconnectedness
- Drifting (melting, breathing, morphing and flowing)
- Colour shifting
- Depth perception distortions
- Perspective distortions
- Symmetrical texture repetition
- Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots)
- Nichols, D. E.; Frescas, S.; Marona-Lewicka, D.; Kurrasch-Orbaugh, D. M. (2002). "Lysergamides of Isomeric 2,4-Dimethylazetidines Map the Binding Orientation of the Diethylamide Moiety in the Potent Hallucinogenic Agent N,N-Diethyllysergamide (LSD)". Journal of Medicinal Chemistry. 45 (19): 4344–4349. :10.1021/jm020153s. 1520-4804. 0022-2623. OCLC 39480771. PMID 12213075.
- Advisory Council on the Misuse of Drugs (ACMD) (June 10, 2014). "Update of the generic definition for tryptamines" (PDF). Government Digital Service. p. 12. Retrieved January 1, 2020.
- Mike Power (January 29, 2014). "The Drug Revolution That No One Can Stop". Matter. Medium. Retrieved January 7, 2020.
- Cole, Krystle (2005). Lysergic. Indianapolis: Dog Ear Publishing. 1-59858-007-8.
- Hamilton Morris (May 1, 2011). "Life Is a Cosmic Giggle on the Breath of the Universe". VICE. Retrieved January 7, 2020.
- Lüscher, Christian; Ungless, Mark A. (2006). "The Mechanistic Classification of Addictive Drugs". PLOS Medicine. 3 (11). :10.1371/journal.pmed.0030437. 1549-1676. 1549-1277. PMID 17105338.
- Nichols, David E. (2016). Barker, Eric L., ed. "Psychedelics". Pharmacological Reviews. 68 (2): 264–355. :10.1124/pr.115.011478. 1521-0081. 0031-6997.
- Strassmann, Rick (1984). "Adverse reactions to psychedelic drugs. A review of the literature". Journal of Nervous and Mental Disease. 172 (10): 577–595. :10.1097/00005053-198410000-00001. 0022-3018. OCLC 1754691. PMID 6384428.
- Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. :10.1007/BF03161089. 1556-9039.
- "Bekendtgørelse om euforiserende stoffer - ni nye stoffer tilføjet" (in Danish). Danish Medicines Ageny. August 31, 2015. Retrieved January 1, 2020.
- "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020.
- "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" (in Latvian). VSIA Latvijas Vēstnesis. November 10, 2005. Retrieved January 1, 2020.
- "31 nya substanser klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten [Public Health Agency of Sweden]. January 26, 2016. Retrieved January 1, 2020.
- "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel,psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien: Änderung vom 2. November 2015" (PDF) (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
Information made possible with:
- PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
- Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
- PubChem National Center for Bio Informatics
- Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
Additional APIs were used to construct this information. Thanks for ChemSpider, NCBI, PubChem etc.
Data is constantly updated so please check back later to see if there is any more available information on this substance.